Search clinical trials for: CMTX-101

Total 6851 results

Novartis Gene Therapies

Completed

Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1

Spinal Muscular Atrophy 1

United States
Teres Bio, Inc.

Completed

Study of TER-101 Topical Ointment in Subjects With Atopic Dermatitis

Atopic Dermatitis

United States
Dynavax Technologies Corporation

Completed

Safety, Pharmacokinetics, and Pharmacodynamics of SD-101 in Healthy Normal Males

Healthy

United States
Auris Medical, Inc.

Completed

AM-101 in the Treatment of Acute Tinnitus 2 (TACTT2)

Tinnitus

United States
Arava Bio Tech Ltd.
Cato Research

Unknown

Safety and Efficacy of AR/101 in Accelerating Re-epithelialization of Split Thickness Wounds

Wounds and Injuries

United States
Vicept Therapeutics, Inc.
Accenture

Completed

Dose Response Study of Patients With Erythematous Rosacea

Erythematous (Type One) Rosacea

United States
Sun Pharmaceutical Industries Limited

Completed

Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

Keratoconjunctivitis Sicca | Dry Eye Disease

United States
CorrectSequence Therapeutics Co., Ltd

Recruiting

A Safety and Efficacy Study Evaluating CS-101 in Subjects With β-Thalassemia Major

Beta-Thalassemia Major

China
Children's Hospital of Fudan University
CorrectSequence Therapeutics Co., Ltd

Recruiting

Base-edited Autologous Hematopoietic Stem Cell Transplantation in Treating Patients With β-thalassemia Major

Beta-Thalassemia

China
Tvardi Therapeutics, Incorporated

Recruiting

Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

United States
Transposon Therapeutics, Inc.

Recruiting

TPN-101 in Aicardi-Goutières Syndrome (AGS)

Aicardi-Goutières Syndrome (AGS)

United Kingdom, France, Italy
Wugen, Inc.

Recruiting

A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

United States, Australia
Corat Therapeutics Gmbh

Recruiting

Evaluation of Safety and Tolerability of COR-101 in Hospitalized Patients With Moderate to Severe COVID-19

Covid19

Germany
Canadian Cancer Trials Group
Canadian Cancer Society (CCS); ATGen Canada Inc; Ontario Institute for Cancer... and other collaborators

Active, not recruiting

Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure (COV-IMMUNO)

Covid-19 | Cancer

Canada
Auris Medical AG

Completed

AM-101 in the Treatment of Acute Tinnitus 3 (TACTT3)

Tinnitus

Germany
1ST Biotherapeutics, Inc.

Completed

Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects

Parkinson's Disease

United States
101 Therapeutics

Active, not recruiting

Study to Evaluate Pharmacokinetics, Safety & Tolerability of 101-PGC-005 in Healthy, Adult, Human Subjects

Virus Diseases | COVID-19 | Infectious Disease | Glucocorticoids Toxicity

India
Sentien Biotechnologies, Inc.

Active, not recruiting

A Study of Cell Therapy for Subjects With Acute Kidney Injury Who Are Receiving Continuous Renal Replacement Therapy

Acute Kidney Injury

United States
InQpharm Group

Completed

Safety and Efficacy of IQP-MM-101 in Reducing Symptoms of Diarrhoea

Diarrhoea

Germany
InQpharm Group

Completed

IQP-PO-101 for the Regulation of Bowel Movement Frequency

Constipation | Irregular Bowel Movement Frequency

Germany
Norgine

Completed

A Study to Evaluate the Safety of TZP-101 (IV Ulimorelin) Administered Post-Operatively in Patients Who Have Undergone Partial Bowel Resection

Postoperative Ileus
Alaunos Therapeutics

Completed

Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers

Hematologic Neoplasms | Non-Hodgkin's Lymphoma | Bone Marrow Neoplasms

United States
Cyrenaic Pharmaceuticals

Completed

Study of CYR-101 in Patients With Schizophrenia

Schizophrenia

France
4SC AG

Completed

SC12267 (4SC-101) for Treatment of Patients With Inflammatory Bowel Disease (ENTRANCE)

Inflammatory Bowel Disease (IBD)

Germany, Bulgaria, Romania
Evotec Neurosciences GmbH
Richmond Pharmacology Limited

Completed

The Effects of a Novel NMDA NR2B-Subtype Selective Antagonist, EVT 101, on Brain Function

Human Volunteers

United Kingdom
Eleusis Therapeutics
Beckley Psytech Pty Ltd

Recruiting

ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression

Depression | Healthy Volunteers | Major Depressive Disorder

United Kingdom
Kythera Biopharmaceuticals

Completed

A Study to Assess Injection Comfort of Two Formulations of ATX-101

Healthy

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Waldenstrom Macroglobulinemia | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma and other conditions

United States
Sunovion Respiratory Development Inc.

Completed

A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD (GOLDEN 6)

COPD

United States
Galderma R&D

Completed

Placebo Controlled Efficacy and Safety Study of CD2475/101 40 mg Tablets vs. Placebo and Doxycycline 100 mg Capsules Once Daily in the Treatment of Inflammatory Lesions of Acne Vulgaris

Acne Vulgaris

United States
Gilead Sciences

Terminated

Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)

Chronic Lymphocytic Leukemia

United States, France, United Kingdom, Germany, Italy
Gilead Sciences

Terminated

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease (Madison)

Myelofibrosis

United States
Gilead Sciences

Terminated

Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States, Spain, Belgium, Canada, United Kingdom, Australia, Denmark, Poland, Ireland, France, Sweden
Mineralys Therapeutics Inc.

Completed

Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension (Target-HTN)

Hypertension, Renal

United States
Surgimab
Erasmus Medical Center; Catharina Ziekenhuis Eindhoven; Leiden University Medical... and other collaborators

Completed

Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas

Metastatic Colorectal Cancer | Colon Cancer | Pancreas Cancer | Recurrent Colorectal Carcinoma | Rectum Cancer

Netherlands
BlueWillow Biologics
National Institute of Allergy and Infectious Diseases (NIAID); University of...

Active, not recruiting

A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults (IN-NE-rH5)

Influenza, Pandemic

United States
Kythera Biopharmaceuticals

Completed

Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101

Healthy | Submental Fat

United States, Canada, Australia, United Kingdom
Primoris Therapeutics

Not yet recruiting

A Study to Evaluate the Safety, Tolerability and Efficacy in Patients With Burn(s)

Burns | Burn Degree Second
China Medical University Hospital

Not yet recruiting

Clinical Investigation on the Treatment of Radiation Induced Dermatitis With FR-101 Chest Dressing

Breast Cancer | Radiation Dermatitis
M.D. Anderson Cancer Center
National Institutes of Health (NIH); Tvardi Therapeutics, Inc

Not yet recruiting

Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of Head and Neck

United States
Shandong TheraWisdom Biopharma Co., Ltd.

Not yet recruiting

The Safety and Efficacy of TWP-101 in Patients With Advanced Solid Tumor

Advanced Solid Tumor

China
Upstream Bio Inc.

Completed

Safety and Blood Levels After a Single Injection of UPB-101 in Healthy Japanese and Non-Japanese Non-East Asian Adults

Healthy

United Kingdom
Canopy Growth Corporation

Completed

Study to Assess the Safety, Tolerability, and Effects of CHI-202 to Support Recovery From Physical Activity

Delayed Onset Muscle Soreness (DOMS)

United States
Dark Canyon Laboratories, LLC

Completed

A Safety and Efficacy Study of DCL-101 Compared to GoLYTELY

Bowel Preparation Before Colonoscopy

United States
NHS Greater Glasgow and Clyde
University of Glasgow; Aurum Biosciences Ltd

Unknown

Perfluorocarbon (ABL-101) Oxygenation for Stroke: Trial With GOLD (Glasgow Oxygen Level Dependent Technology) Imaging Theranostic (POST-IT)

Acute Ischaemic Stroke
InQpharm Group

Completed

Clinical Benefit of a Mouthrinse for the Treatment of Dentine Hypersensitivity

Dentin Sensitivity

Germany
Oregon Center for Applied Science, Inc.
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Interactive Training in Sports Concussion Prevention and Management

Concussion

United States
Université de Sherbrooke
Eli Lilly and Company; Chorus Wellness Inc.; AL-S Pharma AG

Recruiting

Safety and Dosimetry of a New Radiotracer to Detect Misfolded SOD1 Associated With Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

Canada
Shandong TheraWisdom Biopharma Co., Ltd.

Recruiting

Safety, Tolerability and Pharmacokinetics of TWP-101 in Patients With Advanced Melanoma and Urothelial Carcinoma

Advanced Melanoma | Advanced Urothelial Carcinoma

China
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) (OFELIA) (OFELIA)

Muscular Atrophy, Spinal

Brazil, Argentina

Search clinical trials for: CMTX-101

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations